

Supplementary Table 1. Baseline characteristics and clinical features of survivor and non-survivor group in the low APACHE-II score group (< 27.5)

Characteristic	Survivor (n = 39)	Non-survivor (n = 36)	p value
Serum NGAL, ng/mL	383.0 (215.0–713.0)	716.0 (397.5–1,239.8)	0.003
APACHE-II score	22.0 (16.0–24.0)	24.0 (22.0–26.0)	0.012
SOFA score	10.0 (8.0–12.0)	11.0 (10.0–13.0)	0.032
Serum NGAL \geq 511.5 ng/mL	13 (33.3)	23 (63.9)	0.008
APACHE-II score \geq 23.5	13 (33.3)	21 (58.3)	0.030
SOFA score \geq 10.5	19 (48.7)	23 (63.9)	0.186
Age, yr	57.1 \pm 17.1	64.8 \pm 15.9	0.047
Body mass index, kg/m ²	23.6 \pm 3.9	22.3 \pm 3.6	0.168
Male sex	24 (61.5)	19 (52.8)	0.443
C-reactive protein, mg/dL	9.5 (2.7–18.4)	13.5 (8.1–18.5)	0.360
Mechanical ventilation	15 (38.5)	20 (55.6)	0.138
Inotropics administration	18 (46.2)	25 (69.4)	0.042
Indication for CRRT initiation			
Sepsis	13 (33.3)	22 (61.1)	0.016
Postoperation	7 (17.9)	1 (2.8)	0.058
Cardiac	4 (10.3)	4 (11.1)	1.000
Pulmonary	0	1 (2.8)	0.480
Hepatic	8 (20.5)	3 (8.3)	0.136
Renal	2 (5.1)	2 (5.6)	1.000
Malignancy	5 (12.8)	3 (8.3)	0.713
Others	0	0	-
Comorbidities			
Diabetes mellitus	14 (35.9)	9 (25.0)	0.307
Hypertension	14 (35.9)	18 (50.0)	0.217
Chronic kidney disease	6 (15.4)	6 (16.7)	0.880
Cerebro-cardiovascular disease	12 (30.8)	10 (27.8)	0.776
Pulmonary disease	1 (2.6)	1 (2.8)	1.000
Liver disease	12 (30.8)	5 (13.9)	0.081
Dementia	0	1 (2.8)	0.480
Malignancy	7 (17.9)	12 (33.3)	0.126

Values are presented as median (interquartile range), number (%), or mean \pm SD.

APACHE-II, Acute Physiology and Chronic Health Evaluation-II; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement therapy.